For instance, a study exposing BRAF V600E mutated KTC1 thyroid cancer cells to long term vemurafenib showed development of secondary KRAS point mutations, allowing these cells to bypass BRAF inhibition (88). This evidence concerns the gene BRAF and thyroid gland carcinoma.